Crossmark

Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial

Crossref DOI link: https://doi.org/10.1038/s41591-025-03507-y

Published Online: 2025-02-07

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Basch, Ethan https://orcid.org/0000-0003-3813-9318
Schrag, Deborah https://orcid.org/0000-0002-4334-5717
Jansen, Jennifer

Henson, Sydney

Ginos, Brenda

Stover, Angela M.

Carr, Philip

Spears, Patricia A.

Jonsson, Mattias https://orcid.org/0000-0002-0846-3742
Deal, Allison M. https://orcid.org/0000-0003-3526-3938
Bennett, Antonia V.

Thanarajasingam, Gita

Rogak, Lauren

Reeve, Bryce B. https://orcid.org/0000-0002-6709-8714
Snyder, Claire

Bruner, Deborah https://orcid.org/0000-0002-5770-9948
Cella, David

Kottschade, Lisa A.

Perlmutter, Jane

Geoghegan, Cindy

Given, Barbara

Mazza, Gina L. https://orcid.org/0000-0002-5305-6193
Miller, Robert https://orcid.org/0000-0003-0869-6316
Strasser, Jon F.

Zylla, Dylan M.

Weiss, Anna

Blinder, Victoria S.

Wolf, Anna P.

Dueck, Amylou C.
Funding

Funding for this research was provided by:

Patient-Centered Outcomes Research Institute (IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392, IHS-1511-33392)
License Information

Text and Data Mining valid from 2025-02-07

Version of Record valid from 2025-02-07
More Information

Article History

Received: 10 June 2024

Accepted: 13 January 2025

First Online: 7 February 2025

Competing interests

: E.B. received personal fees from Navigating Cancer, AstraZeneca, Resilience, Thyme Care, N-Power Medicine, Verily and the Research Triangle Institute as a scientific advisor. D.S. received personal fees from Pfizer. A.M.S. received personal fees from UroGen Pharma and research funds to her institution from Pfizer Global. P.A.S. received personal fees from Pfizer. G.T. received research funds to her institution from Seagen and Novartis. C.S. received personal fees from Shionogi and Movember and research funds to her institution from Pfizer and Genentech. R.M. is employed by ConcertAI and received meal reimbursements from AstraZeneca. D.C. is the president of FACIT.org and an uncompensated board member of the PROMIS Health Organization. L.A.K. received research funds to her institution from Immunocore. A.W. received personal fees from Merck. The other authors declare no competing interests.

Document is current

Any future updates will be listed below